Faron Pharmaceuticals Ltd: Director/PCA Dealing
Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Dr Juho Jalkanen, Chief Executive Officer of the Company, acquired 22,127 ordinary shares in Faron at price of €2.26 per share on 27 June 2025. Following this purchase, Dr Jalkanen directly holds 1,112,015 ordinary shares in the Company, representing 0.99 per cent of the voting rights in the Company.
Additionally, Dr Juho Jalkanen acquired 2,000 ordinary shares in Faron at a price of 2.27 EUR per share on 27 June 2025 on behalf of his daughter.
Further details are set out in the Notification of Dealing Form below.
Director/PCA | Holding prior to purchase | Number of ordinary shares | Resultant interest in ordinary shares in the Company | Resultant percentage of voting rights in the Company |
Juho Jalkanen | 1,089,888 | 22,127 | 1,112,015 | 0.99% |
Evelina Jalkanen* | Nil | 2,000 | 2,000 | 0,00% |
*Individuals deemed as a PCA to Juho Jalkanen
For more information, please contact:
IR Partners, Finland | +358 44 313 5005 |
FINN Partners, US | +1 847 791-8085 |
Cairn Financial Advisers LLP | +44 (0) 207 213 0880 |
Sisu Partners Oy | +358 (0)40 555 4727 |
About bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a. | Name | a) Juho Jalkanen | |||
2 | Reason for notification |
| |||
a. | Position/Status | a) Chief Executive Officer | |||
b. | Initial notification/ | Initial Notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a. | Name | Faron Pharmaceuticals Ltd. | |||
b. | LEI | 7437009H31TO1DC0EB42 | |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a. | Description of the financial instrument, type of instrument | Ordinary Shares | |||
b. | Nature of the transaction | Purchase of ordinary shares | |||
|
|
| Price(s) per share (p) | Volume(s) |
|
a) €2.26 | a) 22,127 |
| |||
| |||||
d. | Aggregated information |
| |||
e. | Date of the transaction | 27/06/2025 | |||
f. | Place of the transaction | Nasdaq First North Growth Market | |||
SOURCE: Faron Pharmaceuticals
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
